FIG. 1

## **Body Weight**





FIG. 2

## **Lung Collagen**



Collagen Fibrosis Score 0=0% 3=16-40% 1=1-5% 4=41-70% 2=6-15% 5=71-100%

FIG. 3

## **Lung Neutrophils**




FIG. 4 **Lung Lymphocytes** 




FIG. 5 **TGF**-β in BALF





FIG. 6

Total CD45<sup>+</sup> Cells in BALF



**FIG.** 7




FIG. 8





FIG. 9



**FIG. 10** 




FIG. 11

Body Weight, Prophylactic Treatment




FIG. 12

Body Weight, Therapeutic Treatment




FIG. 13
Lung Weight, Prophylactic




FIG. 14
Lung Weight, Therapeutic




FIG. 15
Hydroxyproline, Prophylactic




FIG. 16

Hydroxyproline, Therapeutic




FIG. 17
Sirius Red, Prophylactic




FIG. 18
Sirius Red, Therapeutic





FIG. 19
Ashcroft Scoring, Prophylactic



Data indicates Mean±SEM.

\*p < 0.05, \*\*\*p < 0.001 vs BLM+vehicle one-way ANOVA, followed by Dunnett's multiple comparisons test, n = 8-14.

BLM = Bleomycin

**FIG. 20** 

## **Ashcroft Scoring, Therapeutic**




FIG. 21

Sparsentan, Drug Exposure




FIG. 22
Irbesartan, Drug Exposure




FIG. 23

BMS, Drug Exposure

